CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer
Guoqiang Liu, Shiyu Wang, Loan Duong, Ziyu Zeng, Jing Hui Yang, Yun Zhao, Sharif Rahmy, Shan Feng, Ariana Arce, Lin Jia, Jun Wan, Liang Cheng C, Xuemin Lu, Xin Lü
This study identifies CDH3 as a key driver of basal-like prostate cancer and shows that CDH3-targeted therapies like ADCs and CAR T cells are effective in preclinical models.
bioRxiv · Nov 18, 2025 · PreprintCancer Biology